SP-3204 / Decoy Therapeutics - LARVOL DELTA

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire) - "Salarius Pharmaceuticals, Inc...announces that on December 27, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,535,603, titled 'Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same.' The issued claims cover the composition of matter for novel molecular glue degraders including Salarius’ preclinical cereblon-binding compound, SP-3204, through September 2037....The newly issued patent is based on the molecular glue eragidomide (CC-90009) that is known to target the degradation of GSPT1, a protein that is highly expressed in numerous cancers, including hematologic and solid tumors...SP-3204 is our second novel molecular glue following SP-3164, our lead molecular glue that is expected to enter the clinic later this year."

New trial • Patent • Hematological Malignancies • Oncology • Solid Tumor